Oncology KOL Intelligence, decoded.

Oct 26, 2026, 6:06:19 AM Brian Shields

ESMO 2026 Day 3: Top Trials and KOL Reactions

ESMO 2026 Day 3: KRASCENDO-1 and the crossover question, SAFFRON, HARMONi-GI1, CLARITY-Gastric01, PERSEE, LITESPARK-012, NADINA and more, with physician reactio…

lung cancerbreast cancerkol reactions

Oct 25, 2026, 7:43:15 AM Brian Shields

ESMO 2026: Top Melanoma Trials and KOL Voices

ESMO 2026 Madrid melanoma, October 23–26: investigational INTerpath-001 led physician discussion, followed by the NADINA 3-year update, STARBOARD and TIL data, …

kol reactionsesmo 2026melanoma

Oct 25, 2026, 4:04:36 AM Brian Shields

ESMO 2026 Days 1–2: Top Trials and KOL Reactions

ESMO 2026 Days 1-2: a standing ovation for DeLLphi-305 and the crossover question physicians raised, plus INTerpath-001, VOLGA, NATALEE, PANKU-Breast01 and more…

lung cancerbreast cancerkol reactions

Oct 24, 2026, 12:19:39 PM Brian Shields

The ESMO 2026 Debates from the KOL Social Media Threads

ESMO 2026 physician debates on X, verbatim: INTerpath-001 vs neoadjuvant IO, NATALEE's nominal OS p-value, me-too HER2 ADCs, pCR vs EFS in bladder cancer, KEYNO…

breast cancerkol reactionsesmo 2026

Oct 22, 2026, 11:49:54 AM Brian Shields

The INTerpath-001 Leak: An Embargo Break, a 25% Drop, and What Oncologists Said

ESMO lifted the LBA1 embargo after INTerpath-001 results leaked early: RFS HR 0.58 (95% CI 0.45–0.75). Moderna fell 25%. What oncologists and investors said.

kol reactionsinterpath-001esmo 2026